Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program (airing Monday-Friday, 6 a.m. - 9 a.m. ET). It is a fast-paced, irreverent look at the world of Wall Street, and the longest running show on the network. Kernen is based in CNBC's global headquarters in Englewood Cliffs, N.J.
Prior to his anchoring duties, Kernen was CNBC's On-Air Stock Editor and was featured throughout the business day on CNBC.
Kernen came to CNBC in the 1991 merger with Financial News Network, having joined FNN after a 10-year career as a stockbroker. After training at Merrill Lynch, he rose to the level of vice-president at both EF Hutton and Smith Barney. Focusing on small-to-medium-sized corporations, he managed corporate cash accounts and qualified retirement plans in addition to key employees' personal assets.
Kernen holds a bachelor's degree from the University of Colorado in molecular, cellular and developmental biology as well as a master's degree from Massachusetts Institute of Technology. During his graduate studies, he worked at the MIT Center for Cancer Research, one of the world's premier institutions. His work focused on mouse erythroleukemia cells and resulted in a series of publications in well-known scientific journals including CELL, Developmental Biology and Cold Spring Harbor Symposia on Quantitative Biology.
Follow Joe Kernen on Twitter
Talking Squawk looks at our big interviews with Daryl from "The Walking Dead", Jack Welch, Jim Chanos and T. Boone Pickens. Plus, we debate the merits of megayachts versus kayaks.
Talking Squawk—the official blog of everything "Squawk Box"—is back from hiatus and chock-full of goodies.
Dominic Chu, CNBC’s newest markets reporter, a golfer with an enviable seven handicap talks about his favorite links and his fantasy round for “Unscripted.”
What a week! "Talking Squawk" highlights include earnings out the wazoo, "Carlos Danger" stage names, Cialis performance rankings and National Hot Dog Day.
In Monday's The Good, The Bad, and The Ugly: iPhone 6 sales; a new corporate perception poll; and a German buying spree
Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.
Are corporations paying their fair share of taxes? That depends on where you live—and whom you talk to.
In Friday's Good, Bad and Ugly: The biggest IPO ever; foreign firms buy American; and a tax inversion fix.
Get the best of CNBC in your inbox